Xolair 150 MG/1.2 ML powder VLS
Ended Awarded Last action
- Contract number
- SPE2DR26FHCB8
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $19,740
Award facts
- Contract value 100% obligated
- $19,740.25 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency issued a delivery order valued at $19,740.25 to DMS Pharmaceutical Group Inc. for Xolair 150 mg/1.2 ml powder vials, with a firm fixed-price structure and completion date of January 22, 2026. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, was selected without a set-aside designation, demonstrating competitive capability in unrestricted federal procurement. The company has been registered in the System for Award Management since 2001 and maintains extensive experience distributing pharmaceuticals and medical consumables to Department of Defense facilities.
This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a $500 million ceiling value and runs through December 31, 2036, establishing DMS Pharmaceutical Group as a critical regional pharmaceutical supplier for military healthcare operations worldwide. The PPV-G GEN V contract structure enables the Defense Logistics Agency to issue firm fixed-price delivery orders for a comprehensive range of branded and generic prescription drugs, biologics, and medical consumables to support recurring medical supply needs across the global Department of Defense healthcare system.
Quick answers
Who was awarded contract SPE2DR26FHCB8?
SPE2DR26FHCB8 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 30, 2025.
How much is contract SPE2DR26FHCB8 worth?
The government has obligated $19,740 on SPE2DR26FHCB8.
Is contract SPE2DR26FHCB8 an order under another contract?
Yes. SPE2DR26FHCB8 is a delivery order under SPE2DR25D9205, an indefinite delivery contract.
Was contract SPE2DR26FHCB8 competed?
The extent of competition for SPE2DR26FHCB8 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award